<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01249638</url>
  </required_header>
  <id_info>
    <org_study_id>ML22011</org_study_id>
    <nct_id>NCT01249638</nct_id>
  </id_info>
  <brief_title>Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC</brief_title>
  <official_title>Randomized, Open, Multicenter Phase III Study With Capecitabine Plus Bevacizumab Versus Capecitabine Plus Irinotecan Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient with multiple metastases, not eligible for surgery, might not profit from intensive&#xD;
      chemotherapy regimens. Therefore less intensive regimens focusing on survival and disease&#xD;
      control may be a better choice for first line treatment. Therefore this study investigates&#xD;
      the combination of capecitabine and bevacizumab versus the combination of capecitabine,&#xD;
      bevacizumab and irinotecan. In case of progressive disease, the therapy in patients treated&#xD;
      with capecitabine and bevacizumab is intensified by adding irinotecan. Primary endpoint is&#xD;
      time-of-failure strategy (TFS) comparing both treatment arms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TFS</measure>
    <time_frame>9 months</time_frame>
    <description>Time of Failure Strategy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR, OS, Quality of Life, PFS-1</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">516</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Cap+Bev until PD followed by CAPIRI +Bev</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine + Bevacizumab&#xD;
In case of Progression Escalation to:&#xD;
Capecitabine + Irinotecan + Bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capiri + Bev</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine + Irinotecan + Bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine:2 x 1250 mg/m2 day 1-14 followed by 1 week pause q day 21</description>
    <arm_group_label>Cap+Bev until PD followed by CAPIRI +Bev</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab: 7.5 mg/kg day 1 q day 21</description>
    <arm_group_label>Cap+Bev until PD followed by CAPIRI +Bev</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine: 2 x 800mg/m2 day 1-14 followed by 1 week pause q day 21</description>
    <arm_group_label>Capiri + Bev</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan: 200 mg/m2 day 1 , q day 21</description>
    <arm_group_label>Capiri + Bev</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab: 7.5 mg/kg day 1, q day 21</description>
    <arm_group_label>Capiri + Bev</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon or rectum.&#xD;
&#xD;
          -  Stage IV disease.&#xD;
&#xD;
          -  ECOG 0-1.&#xD;
&#xD;
          -  Patients considered suitable for application of chemotherapy.&#xD;
&#xD;
          -  Age 18 - 75 years.&#xD;
&#xD;
          -  In- or outpatient treatment.&#xD;
&#xD;
          -  Estimated life expectancy &gt; 3 months.&#xD;
&#xD;
          -  Measurable index lesion according to RECIST criteria. Evaluation of tumor&#xD;
             manifestations ≤ 2 weeks prior to treatment start.&#xD;
&#xD;
          -  Effective contraception.&#xD;
&#xD;
          -  Adequate hematologic function: leukocytes &gt;= 3000/µl, neutrophils &gt;= 1500/µl,&#xD;
             platelets &gt;= 100.000/µ, and hemoglobin &gt;= 9g/dl. Bilirubin &lt;= 1,5x upper limit of&#xD;
             normal (ULN). ALAT and ASAT &lt;= 2,5x ULN, in case of liver metastases &lt;= 5x ULN. Serum&#xD;
             creatinine &lt;= 1,5x ULN.&#xD;
&#xD;
          -  No operations within 4 weeks prior to treatment start. No cytologic biopsies within 1&#xD;
             week prior to treatment start. Operation sequels need to be completely healed. Major&#xD;
             operations must not be expected at time of study begin, except for potential secondary&#xD;
             resection of liver metastases. In case of secondary resection of liver metastases,&#xD;
             bevacizumab must be discontinued 6-8 weeks prior to surgery.&#xD;
&#xD;
          -  No relevant toxicities due to prior medical treatment at time of study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  primary resectable metastases&#xD;
&#xD;
          -  heart failure Grade III/IV (NYHA-classification)&#xD;
&#xD;
          -  Prior treatment directed against the epidermal growth factor receptor (EGFR).&#xD;
&#xD;
          -  Prior treatment with bevacizumab.&#xD;
&#xD;
          -  Prior chemotherapy for colorectal cancer, except for adjuvant chemotherapy dating back&#xD;
             &gt; 6 months prior to study entry.&#xD;
&#xD;
          -  Experimental medical treatment within 30 days prior to study entry.&#xD;
&#xD;
          -  Known hypersensitivity reaction to any study medication.&#xD;
&#xD;
          -  Pregnant or breast feeding women (pregnancy needs to be excluded by testing of&#xD;
             beta-HCG).&#xD;
&#xD;
          -  Known or suspected cerebral metastases.&#xD;
&#xD;
          -  Clinically significant coronary heart disease, myocardial infarction within the last&#xD;
             12 months or high risk of uncontrolled arrhythmia.&#xD;
&#xD;
          -  Acute or subacute ileus, chronic inflammatory bowel disease or chronic diarrhea.&#xD;
&#xD;
          -  Abdominal or tracheo-esophageal fistulas, gastrointestinal perforation within 6 months&#xD;
             before study entry&#xD;
&#xD;
          -  Symptomatic peritoneal carcinosis.&#xD;
&#xD;
          -  Severe chronic wounds, ulcera or bone fracture.&#xD;
&#xD;
          -  Uncontrolled hypertension.&#xD;
&#xD;
          -  Severe proteinuria (nephrotic syndrome).&#xD;
&#xD;
          -  Arterial thromboembolic events or hemorrhage within 6 months prior to study entry&#xD;
             (except tumor bleeding surgically treated by tumor resection).&#xD;
&#xD;
          -  Bleeding diatheses or coagulopathy.&#xD;
&#xD;
          -  Full dose anticoagulation.&#xD;
&#xD;
          -  Known DPD-deficiency (special screening not required).&#xD;
&#xD;
          -  Known glucuronidation-deficiency (special screening not required).&#xD;
&#xD;
          -  Contraindication with irinotecan&#xD;
&#xD;
          -  Medical history of other malignant disease within 5 years prior to study entry, except&#xD;
             for basalioma, and in-situ cervical carcinoma if treated with curative intent.&#xD;
&#xD;
          -  Known alcohol or drug abuse.&#xD;
&#xD;
          -  Medical or psychiatric condition which contradicts participation of study.&#xD;
&#xD;
          -  Limited legal capacity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Heinemann, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Munich - Klinikum der Universitaet Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sebastian Stintzing, Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Munich - Klinikum der Universitaet Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clemens Giessen</last_name>
    <role>Study Chair</role>
    <affiliation>University of Munich - Klinikum der Universitaet Muenchen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volker Heinemann, Prof. Dr.</last_name>
    <phone>+49 89 7095 0</phone>
    <email>volker.heinemann@med.uni-muenchen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Munich - Klinikum der Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Heinemann, Prof. Dr. med.</last_name>
      <phone>+49 89 7095 0</phone>
      <email>volker.heinemann@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Clemens Giesse, Dr. med.</last_name>
      <phone>+49 89 7095 0</phone>
      <email>clemens.giessen@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Volker Heinemann, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clemens Giessen, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <last_update_submitted>March 11, 2011</last_update_submitted>
  <last_update_submitted_qc>March 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Volker Heinemann, Prof. Dr. med.</name_title>
    <organization>University of Munich - Klinikum der Universitaet Muenchen</organization>
  </responsible_party>
  <keyword>Bevacizumab</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>mCRC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

